Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-112P (RNA, U1 small nuclear 112, pseudogene) is classified as a pseudogene of the U1 small nuclear RNA (snRNA) family[1][4]. Pseudogenes are nonfunctional copies of gene sequences that usually do not encode functional products. Unlike active U1 snRNA genes (such as RNU1-1, which is essential for pre-mRNA splicing), RNU1-112P does not produce a functionally active RNA and does not participate in known biological processes or pathways[1][4][2]. There is currently no evidence linking RNU1-112P to disease, drug interaction, or use as a biomarker. Its main utility is as a genomic reference for evolutionary and structural analyses within snRNA gene families and pseudogenes. Key context and clarification: - Not a therapeutic target: RNU1-112P is a noncoding RNA pseudogene; there is no evidence it encodes a protein or functional RNA, nor is it targeted by any drugs, used in therapy, or considered a disease or cellular function modulator[1][4]. - Pseudogene status: Unlike functional U1 small nuclear RNA genes (such as RNU1-1 or RNU1-2), which are required for spliceosome function and gene expression regulation[2][3][6], RNU1-112P is annotated as a nonfunctional locus and does not contribute to molecular or cellular activity. - Is_incorrect: If the intent is to identify a therapeutic or biologically relevant RNA target, then "RNU1-112P" is not appropriate—this is a pseudogene, not a functional receptor, enzyme, or other canonical drug target. For structured curation, almost all fields return null except for name, class, and explicit note that it is a pseudogene and not a target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 112, pseudogene (RNU1-112P).